Biotech Buys

Celltech�s little deal is big news.

The final cash deal in May that decided control of Oxford GlycoSciences (OGS), a biotech firm based in the United Kingdom, was on the small side—only about $170 million from Oxford�s London neighbor, the Celltech Group. But the fact that this deal happened at all, and that at least five companies fought hard to acquire the tiny genomics-proteomics-biopharmaceutical hybrid, makes it notable.

News Analysis

Ready or Not

Vive la Differentiation!

Shrinking Staffs

Double Attack

Bull�s-Eye?

» Biotech Buys

Sniffing for SNPs